Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AβPP transgenic mice

Journal of Alzheimer's Disease

Volumn 25, Issue 2, 2011, Pages 295-307

  Yu, Jin ^a   Gattoni Celli, Marco ^a   Zhu, Hong ^a   Bhat, Narayan R ^a   Sambamurti, Kumar ^a   Gattoni Celli, Sebastiano ^a,b   Kindy, Mark S ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; amyloid ; animal models; transgenic mice; vitamin D

Indexed keywords

AMYLOID PRECURSOR PROTEIN; COLECALCIFEROL; NERVE GROWTH FACTOR; CTF 1 TRANSCRIPTION FACTOR; CTF-1 TRANSCRIPTION FACTOR; NUCLEAR FACTOR I; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BIRTH; BONE TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VITAMIN SUPPLEMENTATION; WEANING; ANIMAL; BLOOD; BONE; BRAIN; DIET THERAPY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; LEARNING DISORDER; MAZE TEST; MEMORY DISORDER; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BONE AND BONES; BRAIN; CHOLECALCIFEROL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LEARNING DISORDERS; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; NERVE GROWTH FACTOR; NFI TRANSCRIPTION FACTORS; PLAQUE, AMYLOID; PRESENILIN-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960701615     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101986     Document Type: Article

References (40)

1. Mayeux R (2010) Clinical practice. Early Alzheimer's disease. N Engl J Med 362, 2194-2201.
2. Querfurth HW, La Ferla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
3. Li S, Shankar GM, Selkoe DJ (2010) How do soluble oligomers of amyloid beta-protein impair hippocampal syn-aptic plasticity? Front Cell Neurosci 4, 5.
4. Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, La Violette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selkoe DJ, Johnson KA(2010) Functional alterationsinmem-ory networks in early Alzheimer's disease. Neuromolecular Med 12, 27-43.
5. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101, 1172-1184.
6. Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B (2008) Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model.Biogerontology 9, 375-379.
7. Selkoe DJ (2007) Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. Nutr Rev 65, S329-S343.
8. Sambamurti K, Granholm AC, Kindy MS, Bhat NR, Greig NH, Lahiri DK, Mintzer JE (2004) Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 5, 517-528. (Pubitemid 39004426)
9. 3 in the Skin. Oxford Univ. Press, New York, pp. 734-754.
10. 3 from rat skins irradiated in vitro with ultraviolet light. Arch Bio-chem Biophys 188, 282-286. (Pubitemid 8371779)
11. Haussler MR (1986) Vitamin D receptors: nature and function. Annu Rev Nutr 6, 527-562.
12. Nicolaysen R (1937) Studies upon mode of action of vitamin D, III, The influence of vitamin D absorption of calcium and phosphorus in the rat. Biochem J 31, 122-129.
13. Carlsson A (1952) Tracer experiments on the effects of vitamin D on the skeletal metabolism of calcium and phosphorus. Acta Physiologica Scandinavica 26, 212-220.
14. Fraser DR, Kodicek E (1970) Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228, 764-766.
15. Fraser DR, Kodicek E (1973) Regulation of 25-hydroxy-choleciferol-1- hyrdoxylase activity in kidney by parathyroid hormone. Nature (New Biology) 241, 163-166.
16. Szodoray P, Nakken B, Gaal J, Jonsson R, Szegedi A, Zold E, Szegedi G, Brun JG, Gesztelyi R, Zeher M, Bodolay E (2008) The complex role of vitamin D in autoimmune diseases. Scand J Immun 68, 261-269.
17. Aparna R, Subhashini J, Roy K, Reddy GS, Robinson M, Uskokovic M, Reddy GV, Reddanna P (2008) Selective inhibition of cyclooxygenase-2 (COX-2) by 1a, 25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. J Cellular Biochem 104, 1832-1842.
18. Janjetovic Z, Zmijewski MA, Tuckey RC, De Leon DA, Nguyen MN, Pfeffer LM, Slominski AT (2009) 20-hydroxy-cholecalciferol, product of vitamin D hydroxylation by P450 scc, decreases NF-/c B activity by increasing I/c Ba levels in human keratinocytes. PLoS ONE 4, e5988.
19. McCann JC, Ames BN (2008) Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 22, 982-1001. (Pubitemid 351519955)
20. Nadjar A, Bluthe RM, May MJ, Dantzer R, Parnet P (2005) Inactivation of the cerebral NFkappa B pathway inhibits interleukin-1 beta-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropychophar- macology30, 1492-1499. (Pubitemid 41153121)
21. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MPF, Price DL, Tang F, Markowska AL, Borchelt DR (2005) Episodic-like memory deficits in the Ab PPswe/PS1 d E9 mouse model of Alzheimer's disease: relationships to fj-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18, 602-617. (Pubitemid 40332718)
22. Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: A randomized controlled trial. J Bone Mineral Res 20, 1327-1333. (Pubitemid 41033516)
23. Oudshoorn C, Mattace-Raso FUS, van der Velde N, Colin EM, van der Cammen TJM (2008) Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. Dementia Geriatric Cog Dis 25, 539-543. (Pubitemid 351957417)
24. El-Amouri SS, Zhu H, Yu J, Gage FH, Verma IM, Kindy MS (2008) Neprilysin: an enzyme candidate to treat Alzheimer's disease. Am J Pathol 172, 1342-1354. (Pubitemid 351671547)
25. Hook VY, Kindy M, Hook G (2008) Inhibitors of cathepsin B improve memory and reduce Abeta in transgenic Alzheimer's disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase Afj PP site. J Biol Chem 283, 7745-7753.
26. Brumbaugh PF, Haussler MR (1973) 1a, 25-Dihydroxyvi-tamin D3 receptor: competitive binding of vitamin D analogs. Life Sci 13, 1737-1746.
27. Stumpf WE, Sar M, De Luca HF (1981) Sites of action of 1, 25(OH)2 vitamin D3 in intestinal tract, stomach, kid- ney, skin, pituitary and parathyroid. Science 201, 1188-1190. (Pubitemid 10159658)
28. Prufer K, Veenstra TD, Jirikowski GF, Kumar R (1999) Distribution of 1, 25-dihydroxyvitamin D3 receptor immunoreac-tivity in the rat brain and spinal chord. J Chem Neuroanat 16, 135-145. (Pubitemid 29155499)
29. Kream BE, Reynolds RD, Knutson JC, Eisman JA, De Luca HF (1976) Intestinal cytosol binders of 1, 25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3. Arch Biochem Bio-phys 176, 779-787.
30. Jin CH, Pike JW (1996) Human vitamin D receptor-dependent transactivation in Saccharomyces cerevisiae requires retinoid X receptor. Mol Endocrin 10, 196-205. (Pubitemid 26042551)
31. Demay MB, Gerardi JM, De Luca HF, Kronenberg HM (1990) DNA sequences in the rat osteocalcin gene that bind the 1, 25-dihydroxyvitamin D3 receptor in three kindreds. Mol Endocrin90, 197-201.
32. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, Mac Leod NB, Nagai Y, Bourdeau V, Konstorum A, Lalle-mant B, Zhang R, Mader S, White JH (2005) Large-scale in Silico and microarray-based identification of direct 1, 25-dihydroxyvitamin D3 target genes. Mol Endocrinol 19, 2685-2695. (Pubitemid 41577243)
33. Brachet P, Neveu I, Naveilhan P, Garcion E, Wion D (2005) Vitamin D, a neuroactive hormone: from brain development to pathological disorders. In: Vitamin D, Feldman D, Pike JW, Glorieux FH, eds. Elsevier Academic Press, San Diego, pp. 1779-1789.
34. Wion D, Mac Grogan D, Neveu I, Jehan R, Houlgatte R, Brachet P (1991) 1, 25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J Neurosci Res 28, 110-114.
35. Eyles DW, Rogers F, Buller K, McGrath JJ, Ko P, French K, Burne TH (2006) Developmental vitamin D (DVD) deficiency in the rat alters adult behavior independently of HPA function. Pyschonueroendocrinology 31, 958-964. (Pubitemid 44148913)
36. Cherniack EP, Florez H, Roos BA, Troen BR, Levis S (2008) Hypovitaminosis D in the elderly: from bone to brain. J Nutr Health Aging 12, 366-373. (Pubitemid 351957298)
37. Pardridge WM, Sakiyama R, Coty WA (1985) Restricted transport of vitamin D and A derivatives through the rat blood-brain barrier. JNeurochem 44, 1138-1141. (Pubitemid 15105766)
38. Zehnder D, Bland R, Williams MC, McNich RW, Howie AJ, Stewart PM, Hewison M (2001) Extrarenal expression of 25-hydroxyvitamin D3-1a-hydroxylase. J Clin Endocrin Metab 86, 888-894.
39. Mishra MK, Koli P, Bhowmick S, Basu A (2007) Neuroprotection conferred by astrocytes is insufficient to protect animals from succumbing to Japanese encephalitis. Neu-rochem Int 50, 764-773. (Pubitemid 46452845)
40. Moore ME, Piazza A, McCartney Y, Lynch MA (2005) Evidence that vitamin D3 reverses age-related inflammatory changes in the rat hippocampus. Biochem Soc Trans 33, 573-577. (Pubitemid 41160812)